RFS Increased With Neoadjuvant T-VEC Therapy in Advanced MelanomaJune 7th 2019
Neoadjuvant talimogene laherparepvec (T-VEC) led to a significant improvement in the 1-year recurrence-free survival rate in patients with resectable advanced melanoma compared with surgery alone, according to a randomized trial presented at the 2019 ASCO Annual Meeting.
Newer PD-1 Inhibitor Active With Dabrafenib and Trametinib in BRAF V600+ MelanomaJune 5th 2019
The investigational PD-1 inhibitor spartalizumab demonstrated a high rate of complete responses in combination with dabrafenib and trametinib in patients with previously untreated advanced <em>BRAF </em>V600–mutant melanoma. Patients pooled from 2 parts of the 3-part COMBI-i study demonstrated a CR rate of more than 40%.
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant MelanomaJune 4th 2019
Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Patients With Locally Advanced CSCC See Promising Efficacy with CemiplimabJune 2nd 2019
Cemiplimab demonstrated substantial antitumor activity and induced durable responses in patients with locally advanced cutaneous squamous cell carcinoma who were enrolled in the pivotal EMPOWER-CSCC-1 phase II study, and these results were similar to previously reported data in patients with metastatic CSCC enrolled in the same study.
Patients With Stage III Melanoma Have Sustained Efficacy With Adjuvant Ipilimumab at 7 YearsJune 2nd 2019
Updated data from the phase III EORTC 18071 study showed that patients with surgically resected high-risk, stage III melanoma experienced a 25% reduction in the risk of recurrence or death with adjuvant ipilimumab compared with placebo.
Annual Report Shows Death Rates Declined, Focuses on Patients Aged 20-49June 1st 2019
According to the latest Annual Report to the Nation on the Status of Cancer, cancer death rates have declined in men, women, and children across all cancer types, and have continued to decline between 1999 and 2016. In a special section of this year’s report, however, data show that both cancer incidence and death rates were higher in women aged 20 to 49 compared to male counterparts.
AACR Meeting Focuses on Advances in Immunotherapy Across Several Cancer TypesMay 22nd 2019
Robert L. Ferris, MD, PhD, co-physician editor-in-chief of <em>Targeted Therapies in Oncology</em>, highlights a series of exciting results presented across various topics, which affect cancer research and treatment, during the 2019 AACR Annual Meeting.
Melanoma Investigators Strive to Overcome PD-1 Inhibitor ResistanceMay 17th 2019
Investigators across the globe have expended considerable effort attempting to identify mechanisms of response and resistance to ICIs. The general conclusion is that each patient’s response to immunotherapy is likely complex and highly individualized.
Coverage Concerns Temper Enthusiasm Surrounding CAR T-Cell TreatmentApril 12th 2019
A discussion between regulators and special interest groups has cooled some of the excitement generated by the emergence of chimeric antigen receptor T-cell therapy for treating hematologic cancers.
Novel Immunotherapy Tebentafusp Granted Fast Track Designation for Metastatic Uveal MelanomaApril 12th 2019
The FDA has granted tebentafusp (IMCgp100) a fast track designation for the treatment of patients with HLA-A*0201-positive previously untreated metastatic uveal melanoma, according to Immunocore Limited, the company developing the novel immunotherapy agent.
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel SaysApril 8th 2019
Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical ResultsApril 6th 2019
Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
PD-1/HDAC Inhibitor Combo Active in Recurrent Melanoma After Progression on Anti-PD-1 TherapyApril 4th 2019
Entinostat in combination with pembrolizumab induced responses in patients with recurrent or metastatic melanoma who have progressed on or after prior anti–PD-1 therapy, according to results of a phase II trial.
Challenges Persist With CAR T-Cell Therapy in Pancreatic CancerApril 2nd 2019
The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.
Childhood Cancer Associated With Increased Risk for Developing Skin CancersMarch 27th 2019
According to new data, survivors of childhood cancer who have lived 5 or more years from their primary malignancy may be up to 30 times more likely to develop a skin malignancy compared with the general population.
CMS Mulls Opposition to Downsizing Part D Protected Drug ClassesMarch 15th 2019
The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.